次世代抗体治療の世界市場予測2016-2026

◆英語タイトル:Next-Generation Antibody Therapies Market Forecast 2016-2026
◆商品コード:VGAIN60630
◆発行会社(調査会社):visiongain
◆発行日:2016年4月
◆ページ数:241
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Sigle User(1名利用)GBP1,999 ⇒換算¥291,854見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥437,854見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥729,854見積依頼/購入/質問フォーム
※visiongain社発行の調査レポートは、Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。

販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongain社の日本における正規販売代理店です。visiongain社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、次世代抗体治療の世界市場について調査・分析し、以下の構成でお届けいたします。
1. レポート概要

2. 次世代抗体治療の概要

3. 次世代抗体治療: 世界市場 2016-2026

4. 主要地域市場 2016-2026

5. 抗体薬物複合体: 市場予測とパイプライン 2016-2026

6. 改変抗体: 市場予測とパイプライン 2016-2026

7. 二重特異性抗体: 市場予測とパイプライン 2016-2026

8. 抗体フラグメント・抗体様タンパク質(ALPs): 市場予測とパイプライン 2016-2026

9. バイオシミラー抗体: 市場予測 2016-2026

10. 次世代抗体治療市場の定性分析 2016-2026

11. 調査インタビュー

12. 結論
【レポートの概要】

Next-Generation Antibody Therapies – Your 2016 Guide to Trends, R&D and Predicted Revenues
Where are next-generation antibody therapies heading? Visiongain’s new report shows you potential revenues to 2026, giving R&D trends, opportunities and sales forecasting.

Discover in our study the most promising and lucrative parts of that industry. Our analysis lets you assess forecasted sales at overall world market, submarket, product and regional level. That work shows you results, interviews, trends and opportunities.

Many opportunities remain in that expanding market for new biological drugs. Discover what its future holds, with the following sections explaining how our study can help your work.

Forecasts from 2016-2026 and other analyses show you revenue potentials
Besides revenue forecasting to 2026, our new study shows you recent results, growth rates, and market shares. There you find original analyses exploring developments and business outlooks.

In our report you get 87 tables and 46 charts explaining that market. See what its future holds and the potential gains. Find data to benefit your plans, decisions and proposals.

There you also discover qualitative analyses (including SWOT and STEP analysis), product profiles and commercial developments. You also find our interviews with three companies – Ablynx, arGEN-X and Mersana Therapeutics – giving insight to help you stay ahead.

Sales predictions for the world market and submarkets – see what is possible
Along with revenue prediction for the overall world market, our study shows you revenue forecasts to 2026 for the following five submarkets:
• Antibody-drug conjugates (ADCs)
• Engineered antibodies
• Bispecific antibodies
• Antibody fragments and antibody-like proteins (ALPs)
• Biosimilar antibody therapies.

That investigation discusses what stimulates and restrains business. There discover what is possible for monoclonal antibodies and other agents. You find dynamics of the industry and assess its sales potentials, exploring treatments giving high commercial opportunities.

Leading next-generation therapeutic antibodies – what are their prospects?
How will leading next-generation antibody therapies perform to 2026 at world level? Our study forecasts individual revenues of seven products, showing you what revenues are possible:
• Adcetris
• Kadcyla
• Gazyva/Gazyvaro
• Poteligeo
• Removab
• Blincyto
• Kalbitor.
Discover how high those sales can go. With our study you see what is happening, exploring trends, challenges and opportunities.

Our analysis also breaks its main world forecast into geographical submarkets.

Leading regions – assess prospects for next-generation antibody sales
In addition to analyses of the overall world market, our study lets you explore individual revenue forecasts to 2026 for four regional markets:
• US
• EU5 group
• Asia-Pacific region
• Latin America
• Rest of the World.

With that analysis you see where the highest and fastest expanding revenues can occur. That industry holds great potential for opportunities and rising sales. Discover what is possible.

Potential for market growth – how much expansion possible by 2020?
Our study predicts high revenue growth from 2016 to 2026. Launches of novel therapies, investments from international pharmaceutical companies and increasing demand for treatments for serious chronic diseases will increase those agents’ sales from 2016 to 2026.

Our analysis forecasts that the worldwide next-generation antibodies market will generate $11.6 billion in 2020. There discover capabilities, progress, and commercial prospects, helping you stay ahead in knowledge and benefit your reputation for commercial insight.

Research and development – assess innovation, trends and possibilities
What about R&D – the pipeline for new drugs? Our report explains, covering these fields:
• Antibody-drug conjugates (ADCs)
• Engineered antibodies
• Bispecific antibodies
• Antibody fragments and antibody-like proteins (ALPs)
• Other progress in next-generation antibody development.

Our study also discusses these agents and technologies, among others:
• Site-specific linkers
• Glycosylation or glycoengineering
• Defucosylation
• Amino acid modification
• Enhanced antibody-dependent cell-mediated cytotoxicity (ADCC)
• Bispecific, trispecific and multi-specific antibodies
• Domain fragments
• Single-chain variable fragments
• Alternative scaffolds: DARPins, anticalins, Affibodies, Fynomers, Affilins, Adnectins and i-bodies
• Combination therapies.

R&D is particularly strong for antibody-drug conjugates. Also novel products and biobetters with high safety, efficacy and affordability are in great demand. Our work explains, discussing many issues to help your work.

Issues affecting the next-generation antibody therapies industry from 2016
Our survey discusses forces affecting those companies. There you find discussions of these and other issues:
• Approved products indicating a path to regulatory and market acceptance
• R&D for next generation antibodies – explore technologies and potentials
• Challenges with current monoclonal antibody (mAb) therapies
• Big pharma companies investing in next-generation antibody research and development
• Biosimilars and their effects on the market for those next-generation biologics.

That investigation explains social, technological, economic and political forces, with emphasis on competition and business outlooks. Assess what drives and restrains developers, producers and marketers of those emerging biologic medicines.

7 ways Next-Generation Antibody Therapies Market Forecast 2016-2026 helps you
In these seven main ways, our new report helps your research, analysis, plans, decisions and presentations:
• Revenue forecasts to 2026 for the world next-generation antibody therapies market and 5 segments – discover that industry’s prospects, seeing its sales potentials
• Predicted revenues to 2026 for the leading 4 regional markets – assess sales outlooks in the US, EU5, Asia-Pacific and Latin America
• Sales potentials of 7 leading drugs to 2026 – see how high products’ revenues can go
• Review of R&D – investigate trends and progress, seeing what is possible, finding the most promising developments
• Discussion of what stimulates and restrains leading companies – explore strengths, weaknesses, opportunities and threats, assessing that industry’s prospects
• Outlooks for established competitors and new market entrants – hear what scope exists for companies to increase their business and compete from 2016
• Interviews from our survey, showing views from 3 companies – gain insight from that industry to help your work.

There you gain competitive intelligence found only in our analysis, finding sales potentials. Benefit your influence by exploring commercial progress, opportunities and potentials.

Trying our new study now lets you discover antibody trends, opportunities and forecasts
With our new report, by visiongain’s UK-based in-house analysts, you discover analysis to help you stay ahead in knowledge. See there what the future holds for developers, producers and sellers of therapeutic antibodies. Find data you get nowhere else.

Our investigation is for everyone analysing biopharmaceuticals. There you discover data and forecasts for new antibody-based drugs. Avoid missing out and falling behind in knowledge. Instead please get our new report here now.

【レポートの目次】

1. Report Overview
1.1 Next-Generation Antibody Therapies Overview
1.2 Global Next-Generation Antibody Therapies Market Segmentation
1.3 Why you Should Read this Report
1.4 How this Report Delivers
1.5 Main Questions Answered by This Analytical Study
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain

2. Introduction to Next-Generation Antibody Therapies
2.1 Antibodies: An Overview
2.1.1 Monoclonal versus Polyclonal Antibodies
2.1.2 A Brief History of Antibody Drug Development
2.1.3 The Antibody Manufacturing Process
2.1.4 Trends in Antibody Development
2.2 Defining Next-Generation Antibodies
2.3 Classification of Next-Generation Antibody Therapies
2.4 The Need for Next-Generation Technologies
2.5 Development Trends for Next-Generation Antibodies
2.6 Scope of this Report
2.7 Phases of Clinical Trials

3. Next-Generation Antibody Therapies: World Market 2016-2026
3.1 The World Next-Generation Antibody Therapies Market Overview and Segmentation, 2015
3.2 Leading Next-Generation Antibody Therapies
3.3 World Next-Generation Antibody Therapies Market: Sales Forecast 2016-2026
3.4 How Will Segmental Market Shares Change to 2026?
3.4 World Next-Generation Antibody Therapies Market: Drivers and Restraints 2016-2026

4. Leading Regional Markets 2016-2026
4.1 Regional Breakdown of the World Next-Generation Antibody Therapies Market, 2015
4.2 World Next-Generation Antibody Therapies Market: Regional Forecast 2016-2026
4.3 How Will Regional Market Shares Change to 2026?
4.4 US Next-Generation Antibody Therapies Market 2015-2026
4.5 EU5 Next-Generation Antibody Therapies Market 2016-2026
4.6 Asia-Pacific Next-Generation Antibody Therapies Market 2016-2026
4.7 Latin American Next-Generation Antibody Therapies Market 2016-2026
4.8 The Next-Generation Antibody Therapies Market in the Rest of the World 2016-2026

5. Antibody-Drug Conjugates: Market Forecast and Pipeline 2016-2026
5.1 Market Overview, 2016
5.2 Leading ADCs in 2016
5.3 Antibody-Drug Conjugates: Market Forecast 2016-2026
5.4 The Antibody-Drug Conjugates Market: Drivers and Restraints 2016-2026
5.4.1 Competition for Leading Drugs Will Restrain Growth
5.4.2 Manufacturing ADCs Forms a Challenge
5.5 Adcetris (brentuximab vedotin, Seattle Genetics / Takeda)
5.5.1 Adcetris: Sales 2011-2015
5.5.2 Adcetris Results in AETHERA Trial and Approval for in HL following Stem Cell Transplantation
5.5.3 Expanding Adcetris Indications for Future Revenue Growth
5.5.4 Adcetris Sales Forecast 2016-2026
5.6 Kadcyla (trastuzumab emtansine, Roche)
5.6.1 Mixed Results from Different Clinical Trials
5.6.2 NICE Rejects Kadcyla on Cost Grounds, but it Just Manages to Hold on in the Cancer Drugs Fund List
5.6.3 Kadcyla Sales Forecast 2016-2026
5.7 Mylotarg (gemtuzumab ozogamicin, Pfizer)
5.7.1 Mylotarg to be Relaunched?
5.8 Antibody-Drug Conjugate Platforms
5.8.1 Limited Market Opportunity for Radioconjugation
5.8.2 Seattle Genetics’ Platform Accounted for Over 50% of the Pipeline in 2015
5.8.3 ImmunoGen: TAP Technology
5.8.4 Immunomedics: Lower Potency Cytotoxics for Extended Use
5.8.5 Preclinical Platforms for ADC Development
5.9 ADCs Have Attracted High-Value Deals and will Continue to do so
5.10 Antibody-Drug Conjugates: Pipeline Analysis 2015-2026
5.10.1 The Longest Pipeline in the Next-Generation Antibodies Market
5.10.2 Cancer Is the Only Target for Current Clinical-Stage ADCs
5.11 Antibody-Drug Conjugates: Phase 3 Pipeline
5.11.1 CMC544 (inotuzumab ozogamicin, Pfizer)
5.11.1.1 Granted Breakthrough Therapy Designation
5.11.2 Roche Attempting to Expand Kadcyla Indications and also Possesses some Unique ADCs in the Pipeline
5.11.2.1 RG7596 (polatuzumab vedotin) for NHL and DLBCL
5.11.2.2 RG7599/DNIB0600A (anti-NaPi2b) for Ovarian Cancer
5.11.2.3 RG7450/DSTP3086S (anti-STEAP1) for Prostate Cancer
5.12 Antibody-Drug Conjugates: Phase 2 Pipeline
5.12.1 ABT-414 (anti-EGFR, AbbVie/Seattle Genetics)
5.12.2 BT-062 (indatuximab ravtansine; anti-CD138, Biotest)
5.12.3 CDX-011 (glembatumumab vedotin; anti-glycoprotein NMB, Celldex Therapeutics/Seattle Genetics)
5.12.4 Immunomedics’ IMMU-130 (labetuzumab-SN-38; anti-CEA/CD66e) and IMMU-132 (anti-TROP-2)
5.12.5 MLN0264 (anti-GCC, Millennium Pharmaceuticals/Seattle Genetics)
5.12.6 MM-302 (anti-HER2, Merrimack Pharmaceuticals)
5.12.7 PSMA ADC (anti-PSMA, Progenics Pharmaceuticals/Seattle Genetics)
5.12.8 SAR3419 (coltuximab ravtansine) (anti-CD19, Sanofi)
5.12.9 Seattle Genetics’ Phase 1 and Phase 2 ADCs
5.12.9.1 SGN-CD19A (anti-CD19) for DLBCL and ALL
5.12.9.2 SGN-LIV1A (anti-LIV-1) for Relapsed Breast Cancer
5.12.9.3 SGN-CD33A: Using a New Cytotoxin and Linker Technology
5.12.9.4 SGN-CD70A (anti-CD70, Seattle Genetics)
5.13 Antibody-Drug Conjugates: Phase 1 Pipeline
5.14 Antibody-Drug Conjugates: Preclinical Pipeline
5.15 Future Developments in ADC Technology
5.15.1 Site-Specific Linkage for Improved Safety Profiles

6. Engineered Antibodies: Market Forecast and Pipeline 2016-2026
6.1 Defining an ‘Engineered Antibody’
6.2 Market Overview 2016, and the Leading Engineered Antibodies
6.3 Leading Engineered Antibodies: Market Forecast 2016-2026
6.4 The Engineered Antibodies Market: Drivers and Restraints 2015-2026
6.5 Poteligeo (mogamulizumab, Kyowa Hakko Kirin)
6.5.1 Poteligeo Sales Forecast 2016-2026
6.6 Gazyva / Gazyvaro (obinutuzumab, Roche)
6.6.1 Gazyva as a Challenger in the anti-CD20 Market
6.6.2 Competition beyond Rituxan and Biosimilars
6.6.3 Gazyva Receives Second Approval
6.6.4 Gazyva Sales Forecast 2016-2026
6.7 Engineered Antibodies Platforms
6.7.1 Roche Glycart: GlucoMAb – Glycosylation for Improved ADCC
6.7.2 Kyowa Hakko Kirin: Potelligent – Enhancing ADCC
6.7.3 Glycotope: GlycoExpress
6.7.4 MacroGenics: Fc Optimization
6.7.5 Xencor: XmAb – Modifying Amino Acids in the Fc Domain
6.7.6 Other Platforms for Increased Potency
6.8 Engineered Antibodies: Pipeline Analysis 2016-2026
6.9 Engineered Antibodies: Phase 3 Pipeline
6.9.1 Benralizumab (MedImmune / Kyowa Hakko Kirin)
6.9.2 Elotuzumab (anti-SLAMF7, Bristol-Myers Squibb/AbbVie)
6.9.3 MEDI4736 (anti-PDL1, AstraZeneca)
6.9.4 RG7446/MPDL3280A (anti-PDL1, Roche)
6.9.5 Ublituximab (anti-CD20, TG Therapeutics)
6.10 Engineered Antibodies: Phase 2 Pipeline
6.10.1 Glycotope’s CetuGEX (anti-EGFR), PankoMab-GEX (anti-TA-MUC1) and TrasGEX (anti-HER2)
6.10.2 Margetuximab (anti-HER2, MacroGenics)
6.10.3 MEDI-551 (anti-CD19, AstraZeneca)
6.10.4 MOR-208 (XmAb5574) (anti-CD19, MorphoSys/Xencor)
6.10.5 Teplizumab (anti-CD3, MacroGenics)
6.10.6 BIW-8962 (anti-GM2, Kyowa Hakko Kirin)
6.10.7 XmAb5871 (anti-CD19, Xencor)
6.11 Engineered Antibodies: Phase 1 Pipeline

7. Bispecific Antibodies: Market Forecast and Pipeline 2016-2026
7.1 Bispecific Antibodies: Market Overview, 2016
7.2 Bispecific Antibodies: Market Forecast 2016-2026
7.3 The Bispecific Antibodies Market: Drivers and Restraints 2016-2026
7.4 Removab (catumaxomab, Neopharm)
7.4.1 Removab: Sales Forecast 2016-2026
7.5 Blincyto (blinatumomab, Amgen)
7.5.1 Amgen Files a Supplemental Biologics License Application, and the EU approves Blincyto
7.5.2 Blincyto: Sales Forecast 2016-2026
7.6 Bispecific Antibodies Platforms
7.6.1 BiTE Platform: The Current Market Leader
7.6.2 MacroGenics’ DART Platform Holds Promise
7.6.3 TriomAbs (TRION Pharma): Limited Market Impact 2016-2026
7.6.4 Other Bispecific Antibody Platforms
7.6.4.1 DuoBodies (Genmab)
7.6.4.2 ImmTAC (Immunocore)
7.7 Bispecific Antibodies: Pipeline Analysis 2015-2026
7.7.1 Bispecific Antibodies: Phase 2 and Phase 3 Pipeline
7.7.2 ABT-122 (anti-TNF and IL-17A) and ABT-981 (anti-IL-1α and IL-1β, AbbVie)
7.7.3 AFM13 (anti-CD30 and CD16A, Affimed Therapeutics)
7.7.4 MM-111 (anti-ErbB2 and ErbB3, Merrimack Pharmaceuticals)
7.7.5 MM-141 (anti-IGF-1R and ErbB3, Merrimack Pharmaceuticals)
7.7.6 SAR156597 (anti-IL-4 and IL-13, Sanofi)
7.7.7 Vanucizumab (RG7221; anti-Ang2 and VEGF-A, Roche)
7.8 Bispecific Antibodies: Phase 1, Phase 1/2 and Preclinical Pipeline

8. Antibody Fragments and Antibody-Like Proteins (ALPs): Market Forecast and Pipeline 2016-2026
8.1 Antibody Fragments and ALPs: Market Overview, 2016
8.2 Antibody Fragments and ALPs: Market Forecast 2015-2026
8.3 The Antibody Fragments and ALPs Market: Drivers and Restraints 2016-2026
8.4 Kalbitor (ecallantide, Shire): Shire Completes Acquisition of Dyax and adds Kalbitor to Portfolio
8.4.1 Kalbitor: Sales Forecast 2016-2026
8.5 Antibody Fragments and ALPs Platforms
8.5.1 Single-chain Variable Fragment Platforms
8.5.1.1 ESBATech and Delenex Therapeutics: Two Approaches Using the Same Platform
8.5.1.2 Nanobodies: The Smallest Antibody Fragment
8.5.1.3 Ablynx’s Nanobody Platform Has Created Many Clinical Candidates
8.5.1.4 Domain Antibodies: GSK and Crescendo Biologics
8.5.2 Non-Antibody Protein Scaffolds: Antibody-Like Proteins
8.5.2.1 DARPins: One-Tenth the Size of Antibodies
8.5.2.2 Anticalins (Pieris): Tested in Clinical Trials
8.5.2.3 Affibodies (Affibody)
8.5.2.4 Fynomers (Covagen/Johnson & Johnson)
8.5.2.5 Affilins (Scil Proteins): Three Products in Pre-Clinical Development?
8.5.2.6 Adnectins (Bristol-Myers Squibb)
8.5.2.7 AdAlta: i-bodies
8.5.3 Which Platform Will Lead the Market 2016-2026?
8.6 Antibody Fragments and ALPs: Pipeline Analysis 2016-2026
8.6.1 Ablynx Leads the Pipeline with Six Clinical Projects
8.7 Antibody Fragments and ALPs: Phase 3 Pipeline
8.7.1 Caplacizumab (anti-vWF, Ablynx)
8.7.2 Abicipar (anti-VEGF, Allergan/Molecular Partners)
8.8 Antibody Fragments and ALPs: Phase 2 Pipeline
8.8.1 ALX-0061 (anti-IL-6R, Ablynx/AbbVie)
8.8.2 Ozoralizumab (anti-TNFα, Ablynx )
8.8.3 DLX105 (anti-TNF-α, Delenex Therapeutics)
8.8.4 ESBA1008 (anti-VEGF, Novartis)
8.9 Antibody Fragments and ALPs: Phase 1 Pipeline
8.9.1 ALX-0761 (anti-IL-17A and IL-17F, Ablynx/Merck Serono)
8.9.2 ALX-0171 (anti-respiratory syncytial virus)
8.9.3 ALX-0141 (anti-RANKL, Ablynx/Eddingpharm)
8.9.4 Other Phase 1 Candidates, and the Preclinical Pipeline

9. Biosimilar Antibodies: Market Forecast 2016-2026
9.1 Biosimilar Antibodies: Market Overview, 2016
9.2 Leading Biosimilar Antibodies in 2016.
9.3 Biosimilar Antibodies: Market Forecast 2016-2026
9.4 The Biosimilar Antibodies Market: Drivers and Restraints 2016-2026
9.4.1 New Launches of Biosimilar mAbs in Developed and Emerging Markets
9.4.2 Rising Incidence of Cancer will Drive Demand
9.4.3 Novel mAb Developers Choosing to Develop Biobetters and Next-Generation Therapies in Face of Biosimilar Competition
9.4.4 Will Biosimilars Challenge Next-Generation Antibodies in this Decade?

10. Qualitative Analysis of the Next-Generation Antibody Therapies Market 2016-2026
10.1 SWOT Analysis of the Next-Generation Antibody Therapies Market
10.1.1 Strengths: The Path Towards Market Acceptance
10.1.2 Weaknesses
10.1.2.1 Challenges Exist With Current Monoclonal Antibody Therapies
10.1.3 Opportunities
10.1.3.1 Big Pharma Is Investing Heavily in Next-Generation Pipelines
10.1.4 Threats
10.1.4.1 Will Biosimilars Slow Growth in the Next-Generation Antibody Market?
10.2 STEP Analysis of the Next-Generation Antibody Therapies Market
10.2.1 Social Factors: Rising Demand for Cancer Therapies
10.2.1.1 Cancer Incidence Is Rising Rapidly
10.2.1.2 Next-Generation Antibodies for Personalised Medicine
10.2.2 Technological Developments Will Drive Pipeline Growth
10.2.2.1 There Are Many Competing Platforms
10.2.2.2 Manufacturing Challenges Exist for Most Sectors
10.2.2.3 New Analytical Tools for Target Identification and Protein Characterisation
10.2.3 Economic Pressures
10.2.3.1 Next-Generation Antibodies Are High-Cost
10.2.3.2 Outsourced Manufacturing: CMOs Are Expanding Capabilities
10.2.3.3 Next-Generation Launches for Product Lifecycle Management
10.2.4 Political and Regulatory Issues
10.2.4.1 Regulatory Challenges for Biosimilar Antibodies
10.3 Key Targets for Next-Generation Antibody Development 2016-2026
10.3.1 Oncology Is the Lead Indication in All Sectors
10.3.1.1 HER2 and HER3 for Breast Cancer
10.3.1.2 CD19 and CD20 for Lymphoma and Leukaemia

11. Research Interviews
11.1 Interview with Dr Edwin Moses, CEO, Ablynx, Belgium
11.1.1 The Benefits of Nanobodies over Traditional Antibody Therapies
11.1.2 Manufacturing Nanobodies
11.1.3 Turning Challenges to Advantages
11.1.4 Nanobodies Are Further Developed than Other Antibody Scaffolds
11.1.5 The Commercial Potential for Nanobodies
11.1.6 Next-Generation Antibodies in China and Other Emerging Markets
11.2 Interview with Tim van Hauwermeiren, CEO, arGEN-X, the Netherlands and Belgium
11.2.1 arGEN-X’s Development Pipeline
11.2.2 Enhancing the Activity of ARGX-111
11.2.3 arGEN-X’s SIMPLE Antibody™ Platform
11.2.4 Commercial Prospects for arGEN-X’s Antibodies
11.2.5 Plans for Growth
11.2.6 Opportunities and Challenges for Next-Generation Antibody Developers
11.2.7 Therapeutic Areas for Manufacturers of Antibody Therapies
11.2.8 Other Trends and Developments in the Market
11.3 Interview with Mersana Therapeutics, Cambridge, Massachusetts, USA
11.3.1 Mersana’s Development Pipeline
11.3.2 Advantages of the Fleximer Platform
11.3.3 Future Plans for Mersana
11.3.4 The Outlook for ADCs in 2015-2026

12. Conclusions
12.1 High Growth Potential in the Next-Generation Antibody Therapies Market in 2015-2026
12.2 Current Status of the Market and Leading Segments
12.3 Leading Next-Generation Antibody Therapies Profiled in this Report
12.4 Leading Regional Markets
12.5 Development of the Market to 2026
12.6 Technology Platforms Will Continue to Attract Big Pharma Interest
12.7 Most Developers Continue to Target Cancer
12.8 Strategies for Growth in 2016-2026

Table 2.1 Monoclonal Antibody Types and Sources, 2016
Table 2.2 The Different Phases of Clinical Trials and What They Assess
Table 3.1 World Next-Generation Antibody Therapies Market: Revenue ($m) and Market Share (%) by Segment, 2015
Table 3.2 World Next-Generation Antibody Therapies Market Forecast: Revenue ($m), AGR (%), CAGR (%) by Segment, 2015-2020
Table 3.3 World Next-Generation Antibody Therapies Market Forecast: Revenue ($m), AGR (%), CAGR (%) by Segment, 2021-2026
Table 3.4 World Next-Generation Antibody Therapies Market: Revenue ($m) and Market Share (%) by Segment, 2026
Table 4.1 World Next-Generation Antibody Therapies Market: Revenues ($m) and Market Shares (%) by Region, 2015
Table 4.2 World Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) by Region, 2015-2020
Table 4.3 World Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) by Region, 2021-2026
Table 4.4 Revenue ($m) and Market Shares (%) of Leading Regional Next-Generation Antibody Therapies Markets, 2026
Table 4.5 US Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2015-2020
Table 4.6 US Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2021-2026
Table 4.7 EU5 Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2015-2020
Table 4.8 EU5 Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2021-2026
Table 4.9 Asia-Pacific Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2015-2020
Table 4.10 Asia-Pacific Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2021-2026
Table 4.11 Latin American Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2015-2020
Table 4.12 Latin American Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2021-2026
Table 4.13 Rest of the World Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2015-2020
Table 4.14 Rest of the World Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2021-2026
Table 5.1 ADC Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Drug, 2015-2020
Table 5.2 ADC Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Drug, 2021-2026
Table 5.3 Seattle Genetics: Adcetris Revenue ($m), 2011-2015
Table 5.4 Total Adcetris Revenue (Seattle Genetics and Takeda): Revenue ($m), 2013-2015
Table 5.5 Total Adcetris Revenue Forecast (Seattle Genetics and Takeda): Revenue ($m), AGR (%), CAGR (%), 2015-2020
Table 5.6 Total Adcetris Revenue Forecast (Seattle Genetics and Takeda): Revenue ($m), AGR (%), CAGR (%), 2021-2026
Table 5.7 Kadcyla Revenue Forecast (Roche): Revenue ($m), AGR (%), CAGR (%), 2015-2020
Table 5.8 Kadcyla Revenue Forecast (Roche): Revenue ($m), AGR (%), CAGR (%), 2021-2026
Table 5.9 ADC Pipeline by Platform and Phase, 2015
Table 5.10 ImmunoGen: Collaboration Revenue ($m), 2012-2014
Table 5.11 Selected Preclinical ADC Development Platforms, 2015
Table 5.12 ADC Pipeline by Indication and Phase, 2015
Table 5.13 ADC Pipeline by Indication and Phase, 2015
Table 5.14 Selected Ongoing Clinical Trials for CMC544 (inotuzumab ozogamicin), 2016
Table 5.15 Roche’s Antibody-Drug Conjugates Pipeline, 2015
Table 5.16 Ongoing Clinical Trials for RG7596 (polatuzumab vedotin), 2016
Table 5.17 Antibody-Drug Conjugates: Phase 2 Pipeline, 2015
Table 5.18 Ongoing Clinical Trials for ABT-414, 2016
Table 5.19 Antibody-Drug Conjugates: Phase 1 Pipeline, Table 1, 2015
Table 5.20 Antibody-Drug Conjugates: Phase 1 Pipeline, Table 2, 2015
Table 5.21 Antibody-Drug Conjugates: Preclinical Pipeline, 2016
Table 6.1 Engineered Antibodies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2015 2020
Table 6.2 Engineered Antibodies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2021-2026
Table 6.3 Total Poteligeo Revenue Forecast (Kyowa Hakko Kirin): Revenue ($m), AGR (%), CAGR (%), 2015-2020
Table 6.4 Total Poteligeo Revenue Forecast (Kyowa Hakko Kirin): Revenue ($m), AGR (%), CAGR (%), 2021-2026
Table 6.5 Total Gazyva Revenue Forecast (Roche): Revenue ($m), AGR (%), CAGR (%), 2015-2020
Table 6.6 Total Gazyva Revenue Forecast (Roche): Revenue ($m), AGR (%), CAGR (%), 2021-2026
Table 6.7 Engineered Antibodies Pipeline by Company and Phase, 2015
Table 6.8 Selected Licensing Agreements for the Potelligent Platform and Cell Lines, 2008-2014
Table 6.9 Engineered Antibodies Pipeline by Indication and Phase, 2015
Table 6.10 Engineered Antibodies: Phase 3 Pipeline, 2015
Table 6.11 Engineered Antibodies: Phase 2 Pipeline, 2015
Table 6.12 Margetuximab Recent and Ongoing Clinical Trials, 2016
Table 6.13 MEDI-551 Recent and Ongoing Clinical Trials, 2016
Table 6.14 Engineered Antibodies: Phase 1 Pipeline, 2015
Table 7.1 Bispecific Antibodies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2015-2020
Table 7.2 Bispecific Antibodies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2021-2026
Table 7.3 Removab (Neopharm) Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2020
Table 7.4 Removab (Neopharm) Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2021-2026
Table 7.5 Blincyto Revenue Forecast (Amgen): Revenue ($m), AGR (%), CAGR (%), 2015-2020
Table 7.6 Blincyto Revenue Forecast (Amgen): Revenue ($m), AGR (%), CAGR (%), 2021-2026
Table 7.7 Bispecific Antibodies Pipeline by Company and Phase, 2015
Table 7.8 Selected Preclinical Bispecific Antibody Platforms, 2015
Table 7.9 Bispecific Antibodies Pipeline by Indication and Phase, 2015
Table 7.10 Bispecific Antibodies Pipeline by Indication and Phase, 2015
Table 7.11 Bispecific Antibodies: Phase 1/2 Pipeline, 2015, Table 1
Table 7.12 Bispecific Antibodies: Phase 1 Pipeline, 2015, Table 2
Table 7.13 Bispecific Antibodies: Preclinical Pipeline, 2015
Table 8.1 Antibody Fragments and ALPs Market Forecast: Revenues ($m), AGR (%), CAGR (%),
2015-2020
Table 8.2 Antibody Fragments and ALPs Market Forecast: Revenues ($m), AGR (%), CAGR (%),
2020-2026
Table 8.3 Kalbitor Revenue Forecast (Shire): Revenue ($m), AGR (%), CAGR (%), 2015-2020
Table 8.4 Kalbitor Revenue Forecast (Shire): Revenue ($m), AGR (%), CAGR (%), 2021-2026
Table 8.5 Ablynx: Selected Big Pharma Collaboration Agreements, 2012-2015
Table 8.6 Antibody Fragments and ALPs Pipeline by Company and Phase, 2015
Table 8.7 Antibody Fragments and ALPs Pipeline by Indication and Phase, 2015
Table 8.8 Antibody Fragments and ALPs: Phase 1 Pipeline, 2015
Table 8.9 Antibody Fragments and ALPs: Preclinical Pipeline, 2015
Table 9.1 Top Ten Best-Selling Drugs of 2014 (Within the Overall Pharmaceutical Market): Revenues ($bn), Market Shares (%)
Table 9.2 Biosimilar Monoclonal Antibodies Market and Submarkets Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
Table 9.3 Biosimilar Monoclonal Antibodies Market and Submarkets Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
Table 9.4 Biosimilar Monoclonal Antibodies Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
Table 9.5 Biosimilar Monoclonal Antibodies Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
Table 9.6 Patent Status of Five Leading mAbs, 2016
Table 10.1 Next-Generation Antibody Therapies Market: STEP Analysis, 2016-2026
Table 10.2 Selected CMOs Investing in Next-Generation Antibody Technologies, 2005-2015
Table 10.3 HER2 and HER3-Targeting Next-Generation Antibodies: Pipeline, 2015
Table 10.4 CD19 and CD20-Targeting Next-Generation Antibodies: Pipeline, 2015

Figure 1.1 Global Next-Generation Antibody Therapies Market Segmentation Overview, 2016
Figure 3.1 World Next-Generation Antibody Therapies Market: Revenue ($m) by Segment, 2015
Figure 3.2 World Next-Generation Antibody Therapies Market Forecast: Revenue ($m) by Segment, 2015-2026
Figure 3.3 World Next-Generation Antibody Therapies Market: Revenue ($m) by Segment, 2026
Figure 3.4 World Next-Generation Antibody Therapies Market: Drivers and Restraints, 2016-2026
Figure 4.1 World Next-Generation Antibody Therapies Market: Revenues ($m) by Region, 2015
Figure 4.2 World Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) by Region, 2015-2026
Figure 4.3 World Next-Generation Antibody Therapies Market: Revenue ($m) by Region, 2026
Figure 4.4 US Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2015-2026
Figure 4.5 EU5 Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2015-2026
Figure 4.6 Asia-Pacific Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2015-2026
Figure 4.7 Latin American Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2015-2026
Figure 4.8 Rest of the World Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2015-2026
Figure 5.1 ADC Market Forecast: Revenues ($m), 2015-2026
Figure 5.2 ADC Market: Drivers and Restraints, 2016-2026
Figure 5.3 Seattle Genetics: Adcetris Revenue ($m), 2011-2015
Figure 5.4 Total Adcetris Revenue (Seattle Genetics and Takeda): Revenue ($m), 2013-2015
Figure 5.5 Total Adcetris Revenue Forecast (Seattle Genetics and Takeda): Revenue ($m), 2015-2026
Figure 5.6 Kadcyla Revenue Forecast (Roche): Revenue ($m), 2015-2026
Figure 5.7 ADC Pipeline by Platform, 2015
Figure 5.8 ADC Pipeline by Phase, 2015
Figure 5.9 ADC Pipeline by Indication, 2015
Figure 6.1 Engineered Antibodies Market Forecast: Revenues ($m), 2015-2026
Figure 6.2 Engineered Antibodies Market: Drivers and Restraints, 2016-2026
Figure 6.3 Total Poteligeo Revenue Forecast (Kyowa Hakko Kirin): Revenue ($m), 2015-2026
Figure 6.4 Total Gazyva Revenue Forecast (Roche): Revenue ($m), 2015-2026
Figure 6.5 Engineered Antibodies Pipeline by Company, 2015
Figure 6.6 Engineered Antibodies Pipeline by Indication, 2015
Figure 6.7 Engineered Antibodies Pipeline by Phase, 2015
Figure 7.1 Bispecific Antibodies Market: Drivers and Restraints, 2016-2026
Figure 7.2 Bispecific Antibodies Market Forecast: Revenue ($m), 2015-2026
Figure 7.3 Removab (Neopharm) Revenue Forecast: Revenue ($m), 2015-2026
Figure 7.4 Blincyto Revenue Forecast (Amgen): Revenue ($m), AGR (%), CAGR (%), 2015-2026
Figure 7.5 Bispecific Antibodies Pipeline by Company, 2015
Figure 7.6 Bispecific Antibodies Pipeline by Indication, 2015
Figure 7.7 Bispecific Antibodies Pipeline by Phase, 2015
Figure 8.1 Antibody Fragments and ALPs Market Forecast: Revenues ($m), 2015-2026
Figure 8.2 Antibody Fragments and ALPs Market: Drivers and Restraints, 2016-2026
Figure 8.3 Kalbitor Revenue Forecast (Shire): Revenue ($m), 2015-2026
Figure 8.4 Antibody Fragments and ALPs Pipeline by Company, 2015
Figure 8.5 Antibody Fragments and ALPs Pipeline by Indication, 2015
Figure 8.6 Antibody Fragments and ALPs Pipeline by Phase, 2015
Figure 9.1 Biosimilar Monoclonal Antibody Market Forecast, Split by Product: Revenue ($bn), 2014-2026
Figure 9.2 Biosimilar Monoclonal Antibodies Market Forecast: Revenue ($bn), 2014-2026
Figure 10.1 Next-Generation Antibody Therapies Market: Strengths and Weaknesses, 2016-2026
Figure 10.2 Next-Generation Antibody Therapies Market: Opportunities and Threats, 2016-2026

★調査レポート[次世代抗体治療の世界市場予測2016-2026]販売に関する免責事項
★調査レポート[次世代抗体治療の世界市場予測2016-2026]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆